UCB at ECTS 2022: Highlighting solutions to meet the needs of people living with osteoporosis | UCB
UCB's Global Corporate Website

UCB at ECTS 2022: Highlighting solutions to meet the needs of people living with osteoporosis

Adriaan Snauwaert resized
Posted by
Adriaan Snauwaert, Global Communications & Company Reputation
06-May-2022


The upcoming digital and in-person European Calcified Tissue Society (ECTS) congress in Helsinki, taking place from the 7th – 10th May 2022, will be bringing together leading members of the musculoskeletal field to highlight and discuss the latest opportunities and challenges in this space. We look forward to take part in this congress, as we will be highlighting data published earlier this year, that paves the way to reducing fracture risk and improving the outcomes for people living with osteoporosis.

For this year’s ECTS, 5 abstracts that are supported by UCB were accepted, these include 2 plenary oral presentations, 2 oral presentations and 1 poster, focusing on a range of topics such as osteoporosis treatment, fracture risk and identified vertebral fractures. UCB will also be hosting an industrial symposium on the 8th May with leading experts Dr Ralph Müller, Dr Richard Abel and Dr Roland Chapurlat, who will be discussing the mechanisms by which bone-forming therapies impact bone strength.

Osteoporosis, which affects approximately 200 million people globally, is a condition characterized by fragility fractures due to compromised bone strength.1 UCB is proud to showcase its continuous work at ECTS and continuously works towards improving treatment outcomes for people living with osteoporosis, close the treatment gap and reduce the risk of fragility fractures. 

Stay up to date with the latest UCB news at ECTS 2022 through our social media channels (Twitter, LinkedIn) and get involved using #ECTS2022.
 

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.
Image CAPTCHA
Enter the characters shown in the image.